E-Scape Bio racks up $63 mln Series A
South San Francisco-based E-Scape Bio, a developer of treatments for neurodegenerative diseases, has raised a total of $63 million in Series A funding. OrbiMed led the round with participation from other investors that included Novo Holding A/S, Johnson & Johnson Innovation – JJDC Inc, Novartis Venture Fund, Osage University Partners, Lilly Asia Ventures and Sutter Hill Ventures.
12 July 2017•3 mins read
